Cover Image
市場調查報告書

老年癡呆症治療藥及開發中產品的全球市場分析

Global Alzheimer's Disease Drugs Market & Pipeline Drugs Market Analysis to 2020

出版商 iGate Research Pvt Ltd 商品編碼 360460
出版日期 內容資訊 英文 150 Pages
訂單完成後即時交付
價格
Back to Top
老年癡呆症治療藥及開發中產品的全球市場分析 Global Alzheimer's Disease Drugs Market & Pipeline Drugs Market Analysis to 2020
出版日期: 2015年07月13日 內容資訊: 英文 150 Pages
簡介

老年癡呆症治療藥市場一直處於高風險高報酬率狀態。目前上市的治療藥專利即將到期,但銷售額仍然低迷,同時未滿足需求也仍當相當高,因此還留下莫大的新藥開發機會。

本報告提供全球老年癡呆症治療藥的市場相關分析,提供您治療藥銷售額與今後預測,及老年癡呆症的患病人數和今後預測值,現在正在開發的開發中產品 (概要,臨床實驗進展,銷售額預測),各國詳細趨勢 (銷售額·患病人數與其預測),主要的推動及阻礙市場要素,近來的資本交易·資金籌措趨勢等之調查評估。

第1章 摘要整理

第2章 全球老年癡呆症:治療藥市場與患病人數分析

  • 治療藥的市場規模與其預測 (總計11年份)
  • 患病人數與其預測 (總計11年份)

第3章 全球老年癡呆症市場:各國市場佔有率之預測 (總計8年份)

第4章 全球老年癡呆症市場:治療藥的銷售額與其預測 (到2020年)

  • Exelon (Rivastigmine)
  • Razadyne/Reminyl
  • Memary (Memantine)
  • Ebixa (Memantine)
  • Aricept (Donepezil)
  • Rivastach
  • Namenda (Memantine)
  • Nootropil (Piracetam)
  • Namzaric (Memantine·Donepezil)

第5章 全球老年癡呆症市場:開發中產品分析與銷售額的預測

  • Solanezumab
  • ABT-126
  • Idalopirdine
  • Gantenerumab
  • Crenezumab
  • Lu AE58054
  • BIIB037

第6章 老年癡呆症的治療藥市場與患病人數:各國分析

  • 美國
    • 治療藥的銷售額與其預測 (總計8年份)
    • 患病人數與其預測 (總計11年份)
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 日本
  • 中國
  • 印度

第7章 全球老年癡呆症治療藥市場:主要的資本交易分析

  • 策略聯盟
  • 許可證協定
  • 產業合作
  • 企業合併·收購 (M&A)

第8章 老年癡呆症治療藥的開發活動:資金籌措來源分析

  • National Institute of Health (美國國立衛生研究所)
  • Alzheimers Association (老年癡呆症協會)
  • Cure Alzheimers Fund (老年癡呆症治療基金)
  • Alzheimers Drug Discovery Foundation (老年癡呆症藥物研發基金)
  • BrightFocus Foundation

第9章 全球老年癡呆症治療藥市場:推動因素

  • 人口高齡化的發展
  • 醫療上的未滿足需求
  • 強力開發平台(管線)候補藥促進老年癡呆症治療藥市場
  • 老年癡呆症緩和藥的開發動向

第10章 全球老年癡呆症治療藥市場:課題

  • 缺乏有效的標的與動物模式
  • 臨床實驗設計·實施時的障礙
  • 學術機構的障礙與法規上的課題
  • 老年癡呆症治療藥開發的失敗:神經科學今後的研究開發 (R&D) 批判
  • 老年癡呆症治療藥巨額的開發費用與製藥企業的躊躇
  • 研究活動的後退與前進手段
  • 各國國內的障礙 (美國,法國,德國,英國,日本,中國,印度)

圖表一覽

目錄

Alzheimer's disease is a devastating condition for those afflicted as well as their family members and caregivers; the situation is only getting worse as the population ages. With the ageing global population, the number of patients suffering from Alzheimer's disease is predicted to grow during the forecasting period. Alzheimer's treatment is a high risk, high reward market. Drugs currently available in the market have reached maturity; patent of leading drugs have expired. The current unmet needs represent a huge opportunity for pharmaceutical companies which are developing targeted novel therapies.

Global Alzheimer's Disease Drugs Market and Pipeline Drugs Analysis: In 2014, the global market for Alzheimer's disease drugs was dominated by Namenda and Exelon. Aricept and Memary stands at the third and fourth spot respectively in terms of Alzheimer's disease drugs sales in 2014. Ebixa, Razadyne/Reminyl, Rivastach and Nootropil are the other popular drugs in the Alzheimer's disease market. With the patent expiration of popular drugs the sales of the Alzheimer's drugs has also declined. However, there are several pipeline drugs like Solanezumab, Gantenerumab, Crenezumab and Lu AE58054 among others which are likely to hit the market during the period 2017 - 2020.

Global Alzheimer's Disease Country Wise Analysis: In the Alzheimer's disease drugs market, the United States is the largest market. Japan is the second leading market for Alzheimer's disease drugs market accounting for XXX% market share in 2014. China stands at the third spot in the global Alzheimer's disease drugs market being followed by India with XXX% share in the same year. The EU5 countries together accounted for over XXX% share of the global Alzheimer's disease drugs market in 2014.

iGATE RESEARCH report titled "Global Alzheimer's Disease Drugs Market & Pipeline Drugs Market Analysis to 2020" is a 150 page report with 74 Figures and 10 Tables. This report analyses the Alzheimer's Disease Drugs Market, Alzheimer's Disease Pipeline Drugs Market and Clinical Trials Analysis, Alzheimer's Disease - Country Wise Drugs Market, Country Wise Alzheimer's Disease Prevalence, Major Deals in Alzheimer's Disease Drugs Market Landscape, Funding in Alzheimer's Disease Drugs Research, Driving Factors and Challenges for Alzheimer's Disease Drugs Market.

The Alzheimer's Disease Drugs Market has been analyzed from 7 View Points:

  • 1. Alzheimer's Disease - Drugs Sales and Forecast
  • 2. Alzheimer's Disease - Pipeline Drugs Sales Forecast
  • 3. Alzheimer's Disease Drugs - Country Wise Market and Forecast
  • 4. Alzheimer's Disease - Country Wise Prevalence and Forecast
  • 5. Alzheimer's Disease - Pipeline Drugs Clinical Trials Analysis
  • 6. Alzheimer's Disease - Major Deals in Alzheimer's Drugs Market
  • 7. Alzheimer's Disease - Funding in Alzheimer's Disease Research

The Top 9 Alzheimer's Disease Drugs covered in the report are as follows:

  • 1. Exelon
  • 2. Razadyne/Reminyl
  • 3. Memary
  • 4. Ebixa
  • 5. Aricept
  • 6. Rivastach
  • 7. Namenda
  • 8. Nootropil
  • 9. Namzaric

The 7 Pipeline Alzheimer's Disease Drugs covered in the report are as follows:

  • 1. Solanezumab
  • 2. ABT-126
  • 3. idalopirdine
  • 4. Gantenerumab
  • 5. Crenezumab
  • 6. Lu AE58054
  • 7. BIIB037

The 9 Countries Alzheimer's Disease Drugs Market covered in the report are as follows:

  • 1. United States
  • 2. France
  • 3. Germany
  • 4. Italy
  • 5. Spain
  • 6. United Kingdom
  • 7. Japan
  • 8. China
  • 9. India

The Alzheimer's Disease Drugs Major Deals covered in the report are as follows:

  • 1. Strategic Alliance
  • 2. Licensing Agreement
  • 3. Collaboration Deals
  • 4. Mergers and Acquisitions

Source of Information

iGATE RESEARCH employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from Proprietary Information Database, Primary and Secondary Research Methodologies, and In house analysis by iGATE Research dedicated team of qualified professionals with deep industry experience and expertise.

Research Methodologies

Primary Research Methodologies: Questionnaires, Surveys, Interviews with Individuals, Small Groups, Telephonic Interview, etc.

Secondary Research Methodologies: Printable and Non-printable sources, Newspaper, Magazine and Journal Content, Government And NGO Statistics, white Papers, Information on the Web, Information from Agencies Such as Industry Bodies, Companies Annual Report, Government Agencies, Libraries And Local Councils and a large number of Paid Databases.

Table of Contents

1. Executive Summary

2. Global Alzheimers Disease - Drugs Market and Prevalence Analysis

  • 2.1 Global Alzheimers Disease - Drugs Market and Forecast (2010 - 2020)
  • 2.2 Global Alzheimers Disease - Prevalence and Forecast (2010 - 2020)

3. Global Alzheimers Disease - Country Wise Market Share and Forecast (2013 - 2020)

4. Global Alzheimers Disease - Drugs Sales and Forecast To 2020

  • 4.1 Exelon (Rivastigmine) Sales and Forecast
  • 4.2 Razadyne/Reminyl Sales and Forecast
  • 4.3 Memary (Memantine) Sales and Forecast
  • 4.4 Ebixa (Memantine) Sales and Forecast
  • 4.5 Aricept (Donepezil) Sales and Forecast
  • 4.6 Rivastach Sales and Forecast
  • 4.7 Namenda (Memantine) Sales and Forecast
  • 4.8 Nootropil (Piracetam) Sales and Forecast
  • 4.9 Namzaric (Memantine and Donepezil) Sales and Forecast

5. Global Alzheimers Disease - Pipeline Drugs Analysis and Sales Forecast

  • 5.1 Solanezumab Drugs Analysis and Sales Forecast
    • 5.1.1 About Solanezumab
    • 5.1.2 Clinical Trials
    • 5.1.3 Solanezumab Drugs Sales Forecast
  • 5.2 ABT-126 Drugs Analysis and Sales Forecast
    • 5.2.1 About ABT-126
    • 5.2.2 Clinical Trials
    • 5.2.3 ABT-126 Drugs Sales Forecast
  • 5.3 Idalopirdine Drugs Analysis and Sales Forecast
    • 5.3.1 About Idalopirdine
    • 5.3.2 Clinical Trials
    • 5.3.3 Idalopirdine Drugs Sales Forecast
  • 5.4 Gantenerumab Drugs Analysis and Sales Forecast
    • 5.4.1 About Gantenerumab
    • 5.4.2 Clinical Trials
    • 5.4.3 Gantenerumab Drugs Sales Forecast
  • 5.5 Crenezumab Drugs Analysis and Sales Forecast
    • 5.5.1 About Crenezumab
    • 5.5.2 Clinical Trials
    • 5.5.3 Crenezumab Drugs Sales Forecast
  • 5.6 Lu AE58054 Drugs Analysis and Sales Forecast
    • 5.6.1 About Lu AE58054
    • 5.6.2 Clinical Trials
    • 5.6.3 Lu AE58054 Drugs Sales Forecast
  • 5.7 BIIB037 Drugs Analysis and Sales Forecast
    • 5.7.1 About BIIB037
    • 5.7.2 Clinical Trials
    • 5.7.3 BIIB037 Drugs Sales Forecast

6. Alzheimers Disease Drugs Market and Prevalence - Country Wise Analysis

  • 6.1 United States - Alzheimers Disease Drugs Market and Prevalence Analysis
    • 6.1.1 United States - Alzheimers Disease Drugs Market and Forecast (2013 - 2020)
    • 6.1.2 United States - Alzheimers Disease Prevalence and Forecast (2010 - 2020)
  • 6.2 France - Alzheimers Disease Drugs Market and Prevalence Analysis
    • 6.2.1 France - Alzheimers Disease Drugs Market and Forecast (2013 - 2020)
    • 6.2.2 France - Alzheimers Disease Prevalence and Forecast (2012 - 2020)
  • 6.3 Germany - Alzheimers Disease Drugs Market and Prevalence Analysis
    • 6.3.1 Germany - Alzheimers Disease Drugs Market and Forecast (2013 - 2020)
    • 6.3.2 Germany - Alzheimers Disease Prevalence and Forecast (2012 - 2020)
  • 6.4 Italy - Alzheimers Disease Drugs Market and Prevalence Analysis
    • 6.4.1 Italy - Alzheimers Disease Drugs Market and Forecast (2013 - 2020)
    • 6.4.2 Italy - Alzheimers Disease Prevalence and Forecast (2012 - 2020)
  • 6.5 Spain - Alzheimers Disease Drugs Market and Prevalence Analysis
    • 6.5.1 Spain - Alzheimers Disease Drugs Market and Forecast (2013 - 2020)
    • 6.5.2 Spain - Alzheimers Disease Prevalence and Forecast (2012 - 2020)
  • 6.6 United Kingdom - Alzheimers Disease Drugs Market and Prevalence Analysis
    • 6.6.1 United Kingdom - Alzheimers Disease Drugs Market and Forecast (2013 - 2020)
    • 6.6.2 United Kingdom - Alzheimers Disease Prevalence and Forecast (2012 - 2020)
  • 6.7 Japan - Alzheimers Disease Drugs Market and Prevalence Analysis
    • 6.7.1 Japan - Alzheimers Disease Drugs Market and Forecast (2013 - 2020)
    • 6.7.2 Japan - Alzheimers Disease Prevalence and Forecast (2012 - 2020)
  • 6.8 China - Alzheimers Disease Drugs Market and Prevalence Analysis
    • 6.8.1 China - Alzheimers Disease Drugs Market and Forecast (2013 - 2020)
    • 6.8.2 China - Alzheimers Disease Prevalence and Forecast (2010 - 2020)
  • 6.9 India - Alzheimers Disease Drugs Market and Prevalence Analysis
    • 6.9.1 India - Alzheimers Disease Drugs Market and Forecast (2013 - 2020)
    • 6.9.2 India - Alzheimers Disease Prevalence and Forecast (2010 - 2020)

7. Global Alzheimers Disease Drugs Market - Major Deals Analysis

  • 7.1 Global Alzheimers Disease Drugs Market - Strategic Alliance
  • 7.2 Global Alzheimers Disease Drugs Market - Licensing Agreement
  • 7.3 Global Alzheimers Disease Drugs Market - Collaboration Deals
  • 7.4 Global Alzheimers Disease Drugs Market - Mergers and Acquisitions

8. Global Alzheimers Disease Drugs Research - Funding Analysis

  • 8.1 National Institute of Health (2011 - 2016)
  • 8.2 Alzheimers Association (2011 - 2014)
  • 8.3 Cure Alzheimers Fund (2008 - 2014)
  • 8.4 Alzheimers Drug Discovery Foundation (2008 - 2013)
  • 8.5 BrightFocus Foundation (2010 - 2014)

9. Global Alzheimers Disease Drug Market - Driving Factors

  • 9.1 Growing Aging Population
    • 9.1.1 Global Ageing Indicators
    • 9.1.2 Population Aged 60 or Over: World and Development Regions, 1950 - 2050
    • 9.1.3 Worldwide - Distribution of Population Aged 60 Years or Over By Broad Age Group, 1950 - 2050
  • 9.2 Unmet Medical Needs
  • 9.3 Strong Pipeline Candidate Expected to Drive Alzheimers Disease Drugs Market
  • 9.4 Future Drugs for Disease Modification in Alzheimers Disease

10. Global Alzheimers Disease Drug Market - Challenges

  • 10.1 Lack of Validated Targets & Lack of Animal Models
  • 10.2 Barriers in the Design and Implementation of Clinical Trials
  • 10.3 Barriers in Academia and Regulatory Issues
  • 10.4 Alzheimers Drug Failure: Insinuation for Future Research and Development in Neuroscience
  • 10.5 Costly Alzheimers Drug Development Dissuade Drug Companies
  • 10.6 Research Setbacks and Stepping Stones
  • 10.7 Country Wise Barriers to Growth for Alzheimers Disease Drugs Market
    • 10.7.1 Unite States
    • 10.7.2 France
    • 10.7.3 Germany
    • 10.7.4 United Kingdom
    • 10.7.5 Japan
    • 10.7.6 China
    • 10.7.7 India

List of Figures:

  • Figure 2-1: Global - Alzheimers Disease Drugs Market (Million US$), 2010 - 2014
  • Figure 2-2: Global - Forecast for Alzheimers Disease Drugs Market (Million US$), 2015 - 2020
  • Figure 2-3: Global - Alzheimers Disease Prevalence (Million), 2010 - 2014
  • Figure 2-4: Global - Forecast for Alzheimers Disease Prevalence (Million), 2015 - 2020
  • Figure 4-1: Global - Exelon Drugs Sales (Million US$), 2003 - 2014
  • Figure 4-2: Global - Forecast for Exelon Drugs Sales (Million US$), 2015 - 2020
  • Figure 4-3: Global - Razadyne/Reminyl Drugs Sales (Million US$), 2010 - 2014
  • Figure 4-4: Global - Forecast for Razadyne/Reminyl Drugs Sales (Million US$), 2015 - 2020
  • Figure 4-5: Global - Memary Drugs Sales (Million US$), 2011 - 2014
  • Figure 4-6: Global - Forecast for Memary Drugs Sales (Million US$), 2015 - 2019
  • Figure 4-7: Global - Ebixa Drugs Sales (Million US$), 2003 - 2014
  • Figure 4-8: Global - Forecast for Ebixa Drugs Sales (Million US$), 2015 - 2020
  • Figure 4-9: Global - Aricept Drugs Sales (Million US$), 2009 - 2014
  • Figure 4-10: Global - Forecast for Aricept Drugs Sales (Million US$), 2015 - 2019
  • Figure 4-11: Global - Rivastach Drugs Sales (Million US$), 2011 - 2014
  • Figure 4-12: Global - Forecast for Rivastach Drugs Sales (Million US$), 2015 - 2020
  • Figure 4-13: Global - Namenda Drugs Sales (Million US$), 2003 - 2014
  • Figure 4-14: Global - Forecast for Namenda Drugs Sales (Million US$), 2015 - 2020
  • Figure 4-15: Global - Nootropil Drugs Sales (Million US$), 2004 - 2014
  • Figure 4-16: Global - Forecast for Nootropil Drugs Sales (Million US$), 2015 - 2020
  • Figure 4-17: Global - Forecast for Namzaric Drugs Sales (Million US$), 2015 - 2020
  • Figure 5-1: Global - Forecast for Solanezumab Drugs Sales (Million US$), 2017 - 2020
  • Figure 5-2: Global - Forecast for ABT-126 Drugs Sales (Million US$), 2017 - 2020
  • Figure 5-3: Global - Forecast for Idalopirdine Drugs Sales (Million US$), 2017 - 2020
  • Figure 5-4: Global - Forecast for Gantenerumab Drugs Sales (Million US$), 2017 - 2020
  • Figure 5-5: Global - Forecast for Crenezumab Drugs Sales (Million US$), 2018 - 2020
  • Figure 5-6: Global - Forecast for Lu AE58054 Drugs Sales (Million US$), 2017 - 2019
  • Figure 5-7: Global - Forecast for BIIB037 Drugs Sales (Million US$), 2019 - 2020
  • Figure 6-1: United States - Alzheimers Disease Drugs Market (Million US$), 2013 - 2014
  • Figure 6-2: United States - Forecast for Alzheimers Disease Drugs Market (Million US$), 2015 - 2020
  • Figure 6-3: United States - Alzheimers Disease Prevalence (Thousand), 2012 - 2014
  • Figure 6-4: United States - Forecast for Alzheimers Disease Prevalence (Thousand), 2015 - 2020
  • Figure 6-5: France - Alzheimers Disease Drugs Market (Million US$), 2013 - 2014
  • Figure 6-6: France - Forecast for Alzheimers Disease Drugs Market (Million US$), 2015 - 2020
  • Figure 6-7: France - Alzheimers Disease Prevalence (Thousand), 2012 - 2014
  • Figure 6-8: France - Forecast for Alzheimers Disease Prevalence (Thousand), 2015 - 2020
  • Figure 6-9: Germany - Alzheimers Disease Drugs Market (Million US$), 2013 - 2014
  • Figure 6-10: Germany - Forecast for Alzheimers Disease Drugs Market (Million US$), 2015 - 2020
  • Figure 6-11: Germany - Alzheimers Disease Prevalence (Thousand), 2012 - 2014
  • Figure 6-12: Germany - Forecast for Alzheimers Disease Prevalence (Thousand), 2015 - 2020
  • Figure 6-13: Italy - Alzheimers Disease Drugs Market (Million US$), 2013 - 2014
  • Figure 6-14: Italy - Forecast for Alzheimers Disease Drugs Market (Million US$), 2015 - 2020
  • Figure 6-15: Italy - Alzheimers Disease Prevalence (Thousand), 2012 - 2014
  • Figure 6-16: Italy - Forecast for Alzheimers Disease Prevalence (Thousand), 2015 - 2020
  • Figure 6-17: Spain - Alzheimers Disease Drugs Market (Million US$), 2013 - 2014
  • Figure 6-18: Spain - Forecast for Alzheimers Disease Drugs Market (Million US$), 2015 - 2020
  • Figure 6-19: Spain - Alzheimers Disease Prevalence (Thousand), 2012 - 2014
  • Figure 6-20: Spain - Forecast for Alzheimers Disease Prevalence (Thousand), 2015 - 2020
  • Figure 6-21: United Kingdom - Alzheimers Disease Drugs Market (Million US$), 2013 - 2014
  • Figure 6-22: United Kingdom - Forecast for Alzheimers Disease Drugs Market (Million US$), 2015 - 2020
  • Figure 6-23: United Kingdom - Alzheimers Disease Prevalence (Thousand), 2012 - 2014
  • Figure 6-24: United Kingdom - Forecast for Alzheimers Disease Prevalence (Thousand), 2015 - 2020
  • Figure 6-25: Japan - Alzheimers Disease Drugs Market (Million US$), 2013 - 2014
  • Figure 6-26: Japan - Forecast for Alzheimers Disease Drugs Market (Million US$), 2015 - 2020
  • Figure 6-27: Japan - Alzheimers Disease Prevalence (Thousand), 2010 - 2014
  • Figure 6-28: Japan - Forecast for Alzheimers Disease Prevalence (Thousand), 2015 - 2020
  • Figure 6-29: China - Alzheimers Disease Drugs Market (Million US$), 2013 - 2014
  • Figure 6-30: China - Forecast for Alzheimers Disease Drugs Market (Million US$), 2015 - 2020
  • Figure 6-31: China - Alzheimers Disease Prevalence (Thousand), 2010 - 2014
  • Figure 6-32: China - Forecast for Alzheimers Disease Prevalence (Thousand), 2015 - 2020
  • Figure 6-33: India - Alzheimers Disease Drugs Market (Million US$), 2013 - 2014
  • Figure 6-34: India - Forecast for Alzheimers Disease Drugs Market (Million US$), 2015 - 2020
  • Figure 6-35: India - Alzheimers Disease Prevalence (Thousand), 2010 - 2014
  • Figure 6-36: India - Forecast for Alzheimers Disease Prevalence (Thousand), 2015 - 2020
  • Figure 8-1: National Institute of Health - Alzheimers Disease Research Funding (Million US$), 2011 - 2014
  • Figure 8-2: National Institute of Health - Forecast for Alzheimers Disease Research Funding (Million US$), 2015 - 2016
  • Figure 8-3: Alzheimers Association - Alzheimers Disease Research Funding (Million US$), 2011 - 2014
  • Figure 8-4: Cure Alzheimers Fund - Alzheimers Disease Research Funding (Million US$), 2008 - 2014
  • Figure 8-5: Alzheimers Drug Discovery Foundation - Alzheimers Disease Research Funding (Million US$), 2008 - 2013
  • Figure 9-1: Worldwide - Population Aged 60 or Over: World and Development Regions, 1950, 1975, 2009, 2025 & 2050
  • Figure 9-2: Worldwide - Old-Age Dependency Ratio: Major Areas, 2009 & 2050
  • Figure 9-3: Worldwide - Distribution of population aged 60 years or over by broad age group, 1950 - 2050
  • Figure 9-4: Global - Forecast for Alzheimers Disease Pipeline Drugs Market (Million US$), 2017 - 2020
  • Figure 10-1: Unsuccessful Alzheimers Drug Development (Number), 1998 - 2011

List of Tables:

  • Table 3-1: Country Wise - Alzheimers Disease Drugs Market Share (Percent), 2013 - 2014
  • Table 3-2: Country Wise - Forecast for Alzheimers Disease Drugs Market Share (Percent), 2015 - 2020
  • Table 7-1: Global Alzheimers Disease Drugs Market - Strategic Alliance, 2003 - 2015
  • Table 7-2: Global Alzheimers Disease Drugs Market - Licensing Agreement, 2007 - 2015
  • Table 7-3: Global Alzheimers Disease Drugs Market - Collaboration Deals, 2005 - 2015
  • Table 7-4: Global Alzheimers Disease Drugs Market - Mergers and Acquisitions, 2008 - 2015
  • Table 8-1: BrightFocus Foundation - Alzheimers Disease Research Funding (Million US$), 2010 - 2014
  • Table 9-1: Global - Ageing Indicators (Percent), 2011/2012 - 2050
  • Table 9-2: Global - Population (Number), 2011/2012 - 2050
  • Table 9-3: Ten Countries or Areas with the Aging Populations 1950,1980,2013,2050 and 2100(Medium Variant)
Back to Top